FDA moves to cut expert panel input on new drugs

(By: Alexandra Murphy for Becker’s Hospital Review)

The FDA is moving to scale back its long-standing use of expert panels to review drug applications, KFF Health News reported Sept. 12.

George Tidmarsh, MD, PhD, director of the FDA’s Center for Drug Evaluation and Research, said the agency would prefer to move away from convening advisory committees for individual drug approvals, calling them “redundant” and burdensome for regulators and drugmakers. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.